Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37

Benzinga · 1d ago
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.